Dr. Lily Koo Lin, MD

Dr. Lin practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Lin's NPI, 1306908108, was assigned on December 15, 2006. Dr. Lin graduated from Harvard Medical School in 2001. Dr. Lin holds California license A90256.

Dr. Lin's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Lin's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Lin to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Lin is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Lin is licensed in California.

Dmand AI lists conjunctivitis, dry eye, eyelid inflammation, vision problems and visual impairment and blindness among the conditions Dr. Lin treats.

CMS data shows 1,238 Medicare services from Dr. Lin across 16 procedure codes in 2024, for 587 Medicare patients. Medicare paid $135,880 for them.

CMS counts 587 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 256 patients. 72% of them have high cholesterol, and 70% have high blood pressure. 24% are also on Medicaid. Their average risk score is 1.20, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 67, with 62% women.

In 2024, Dr. Lin wrote 384 Medicare Part D claims for 239 patients. 83% of them were for generic drugs. CMS names the drug for 311 of them, across 5 drugs with 11 or more claims each, at $2,804 in total drug cost. In 2023, CMS named 369 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 24 papers to Dr. Lin, published from 2018 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Eyelid Diseases, Orbital Neoplasms and Tomography, X-Ray Computed. Dr. Lin has published most often in J Emerg Trauma Shock. Dr. Lin's most frequent co-authors are Justin Blake Hellman, MD, Colin Bacorn, MD and Esther S. Kim, MD.

CMS Open Payments shows 2 general payments to Dr. Lin from 1 drug or device company from 2020 to 2021. Honoraria make up the largest share, 100% of the total. Horizon Pharma plc paid the most, $6,000.

Dr. Lin graduated from Harvard Medical School in 2001. Dr. Lin is a member of AAO and ACS.

Dr. Lin is in network with 19 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.